Abstract. The present study aimed to detect myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibodies in serum specimens of patients with recurrent optic neuritis (RON) through establishing 293 cells with stable expression of MOG and the complete genomic sequence as the substrate using a cell-based assay (CBA). Furthermore, the clinical features of MOG antibody-positive recurrent optic neuritis (MOG-RON) were assessed. A total of 43 RON patients admitted to Beijing Tongren Hospital from December 2014 to May 2015 were enrolled, including 11 males and 32 females. The serum was collected from all patients, and the MOG and AQP4 antibodies were detected via the CBA. According to the results, the 43 patients were divided into four groups, namely the MOG antibody-positive group (n=11), the AQP4 antibody-positive group (n=20), the MOG/AQP4 antibody-positive group (n=1) and the MOG/AQP4 antibody-negative group (n=11). Clinical data were collected and all patients were followed up for 6 months, with parameters observed including the visual acuity, visual field and ocular fundus. The differences in the demographics, clinical features, characteristics of imaging examination, vision at onset and visual function recovery at 6 months after treatment were compared among the different groups. The characteristics of MOG antibody-positive RON were summarized. Of the 43 RON patients, 2.33% was both MOG and AQP4 antibody-positive, 27.91% were MOG antibody-positive. Compared with the AQP4-RON patients, there were relatively less MOG-RON patients (63.6 vs. 95.0%) and the canal segment and intracranial segment of the optic canal were less involved (P<0.05). The visual acuity at onset of MOG-RON was not inferior to that of AQP4-RON, and the visual recovery degree of MOG-RON was better (P<0.05). MOG antibody may be detected in the serum of certain RON patients, which have unique and different characteristics from AQP4 antibody-positive RON patients, so it may be used as a prognostic biomarker for RON. Furthermore, MOG antibody is present in the serum of patients with neuromyelitis optica spectrum disorders and may be a potential biomarker for these conditions.
Introduction
Optic neuritis (ON) refers to a spectrum of inflammatory lesions involving the optic nerve; it is a blinding optic nerve disease that occurs most frequently in young and middle-aged individuals. The most common type is idiopathic ON, which is further subdivided into idiopathic demyelinating optic neuritis (IDON), also known as multiple sclerosis-associated optic neuritis (MS-ON), neuromyelitis optica-associated optic neuritis (NMO-ON) and ON associated with other central nervous system demyelinating diseases (1) . NMO-ON has a higher disability rate compared with IDON, and an aquaporin-4 (AQP4) immunoglobulin G (IgG) (+) status has a decisive role in the diagnosis of NMO-ON. The probability of progressing to NMO-ON in AQP4 IgG (+) patients is significantly higher than that of AQP4 IgG (-) patients, and the rate of progression to NMO-ON is faster in AQP4 IgG (+) patients. Detection of AQP4 IgG, as a clinical biomarker for identifying NMO-ON and other demyelinating diseases, is helpful for the early diagnosis and prognostication of NMO-ON patients. However, a clinical study indicated that 10-20% of NMO-ON patients have an AQP4 IgG (-) status (2) .
New diagnostic criteria for NMO-ON were developed by the International NMO Diagnostic Group in 2015 (3); diagnostic criteria for serum-negative NMO-ON were proposed, and it was suggested to actively search for potential alternative biomarkers for AQP4 IgG (-) NMO-ON patients. It has been reported that AQP4 IgG (-) NMO-ON patients are myelin oligodendrocyte glycoprotein (MOG) IgG (+) (4, 5) , and it is therefore speculated that MOG IgG is involved in the pathogenesis in these serum AQP4 IgG (-) NMO-ON patients. Saadoun et al (6) microinjected MOG IgG, sourced from patients with NMO, into mouse brains and compared the results with those obtained by AQP4 IgG injection. The results indicated that MOG IgG caused myelin changes
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and altered the expression of axonal proteins within two weeks, but did not produce any inflammation, axonal loss or neuronal or astrocyte death, while AQP4 IgG produced complement-mediated myelin loss, and neuronal and astrocyte death with limited recovery at two weeks. In addition, MOG IgG is also detected in the serum of certain adolescent patients with acute disseminated encephalomyelitis and multiple sclerosis; besides intracranial lesions, these patients also suffer from ON. Therefore, MOG IgG should be actively screened for ON patients with an unknown cause. Data collection. The demographic data (onset age and sex) and clinical features, including the course of the disease, monocular/binocular involvement, eye pain, optic disc edema, worst visual acuity at onset, worst videofluoroscopic swallowing study (VFSS) at onset, visual recovery after treatment with prednisone and/or immunosuppressive agents, VFSS score after treatment, onset frequency of ON, involvement of intraorbital segment, canal segment and intracranial segment of optic nerve and optic chiasma, the presence of other lesions involving the central nervous system, other autoimmune abnormalities (e.g., anti-nuclear antibody, anti-extractable nuclear antigens antibody spectrum, anti-double-stranded DNA antibody, human leukocyte antigen-B27, anti-neutrophil cytoplasmic antibodies and cardiolipin antibody) of patients were collected. AQP4 and MOG IgG in the serum of patients were detected via the cell-based assay (CBA). All patients were treated with methylprednisolone in the acute phase, and certain patients received the immunosuppressive therapy during the process of hormone reduction. One patient was diagnosed with multiple sclerosis and treated with interferon. All patients were followed up, and the visional recovery of patients at 6 months after the last onset was recorded via outpatient review upon visitation to the clinc. Observational indexes. The visual function data of the 43 patients enrolled were collected and the visual impairment of 83 affected eyes was observed. A corrected visual acuity of the affected eye of >0.1 indicated relatively good visual acuity, while that of ≤0.1 indicated poor visual acuity. Visual function VFSS score were determined prior to and at 6 months after treatment with methylprednisolone and/or immunosuppressive agents.
Patients and methods

Patients
Statistical analysis. Statistical analysis was performed using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). A normality test was performed for continuous variables; data with a normal distribution were expressed as the mean ± standard deviation, while those with a skewed distribution were expressed as the median [25% quartile-75% quartile (Q25-Q75)]. One-way analysis of variance was used for intergroup comparisons, followed by the Least-Significant Difference test as a post-hoc test, while the Kruskal-Wallis test followed by a Mann-Whitney U post-hoc test with Bonferroni's correction was applied in the case of an abnormal distribution. The chi-square test was used for categorical variables. The demographics, clinical features, characteristics of laboratory and imaging examinations, vision at onset and visual function recovery at 6 months after treatment were compared among the MOG IgG (+) group, AQP4 IgG (+) group, MOG/AQP4 IgG (+) and MOG/AQP4 IgG (-) groups. P<0.05 was considered to indicate a statistically significant difference. course of disease of 16 years and a history of 15 attacks who had acute ON in both eyes. The patient presented with acute myelitis involving >3 segments, postrema syndrome and acute diencephalic syndrome. As presented in Fig. 1A -D, the brain MRI coronal short-time inversion recovery revealed that the intraorbital segment, canal segment and intracranial segment of the optic nerve and optic chiasma had become thinner and the signal was increased when compared with earlier images obtained from patients prior to the study. As presented in Fig. 1E -H, the brain MRI sagittal T2 fluid-attenuated inversion recovery revealed an abnormal signal in the bilateral basal ganglia, thalamus, lateral ventricle, brain stem and corpus callosum. As presented in Fig. 1I -K, cervical MRI sagittal T2-weighted images revealed an abnormal signal in medullary-C2 and C5-T1.
Results
Case presentation of a NMO-ON patient with MOG
Detection of MOG IgG via CBA. The 293 cells with stable expression of the complete genomic sequence of MOG were successfully constructed. MOG IgG was detected via a CBA and observed under a fluorescence microscope. As presented in Fig. 2 , the representative images demonstrated that the cells incubated with serum from the MOG IgG (+) and AQP4 (+) patients had green fluorescence while DAPI-stained nuclei exhibited blue fluorescence. Tables I and II , the AQP4 IgG (+) group was mostly comprised of females compared with the MOG IgG (+) group and the MOG/AQP4 IgG (-) group (P<0.05).
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Compared with the MOG/AQP4 IgG (-) group, optic disk edema was rarer with fewer attacks in the AQP4 IgG (+) group (P<0.05); however, no statistically significant difference was identified between the MOG IgG (+) and the AQP4 IgG (+) and MOG/AQP4 IgG (-) groups. Optic nerve MRI indicated that the intraorbital segments of the optic nerve were involved in the three groups, but the canal segment and intracranial segment of the optic nerve in the AQP4 IgG (+) group were more significantly involved than those in the other two groups (P<0.05). The optic chiasma was more significantly involved in the AQP4 IgG (+) group than that in the MOG/AQP4 IgG (-) group (P<0.05), and there was no statistically significant difference in the involvement of optic chiasma between the MOG IgG (+) group and the other two groups. There were no statistically significant differences in the age at onset, occurrence of eye pain, course of disease, intracranial lesions, spinal cord involvement and other immune indexes among the three groups.
Comparison of visual function prognosis of patients. All patients enrolled were followed up at the clinic 6 months after onset, with items assessed including visual acuity, visual field and ocular fundus. All of the patients received the same treatment. Prior to treatment, poor visual acuity was determined in 10 eyes (50.0%) of the MOG IgG (+) group, 33 eyes (84.6%) of the AQP4 IgG (+) group and 13 eyes (59.1%) of the MOG/AQP4 IgG (-) group. At 6 months after treatment, poor visual acuity was still present in 2 eyes (10.0%) of the MOG IgG (+), 20 eyes (51.3%) of the AQP4 IgG (+) and 2 eyes (9.1%) of the MOG/AQP4 IgG (-) group (Fig. 4) . The vision at onset was worse and the recovery was poorer in the AQP4 IgG (+) group compared with those in the MOG IgG (+) group and MOG/AQP4 IgG (-) groups (P<0.05; Table I ).
As presented in Table I , the VFSS score was relatively lower with the worst visual function after onset and the visual function recovery after treatment was better in the MOG IgG (+) group compared with that in the AQP4 IgG (+) group (P<0.05). As presented in Figs. 5 and 6, although 1 case in the MOG IgG (+) group (9.09%) had a poor recovery of visual function, the remaining 10 cases (90.91%) had a better recovery of visual function, and the VFSS score after treatment ranged between 1 and 3. The majority of patients in the AQP4 IgG (+) group (14 cases, 70.00%) had a poor visual function recovery. After treatment, the VFSS score ranged between 4 and 6; a small number of AQP4 IgG (+) patients (6 cases, 30.00%) had a better recovery, and the score ranged between 1 and 3.
Association between MOG IgG and NMO-ON.
Out of the 12 MOG IgG (+) patients, 2 met the diagnostic criteria for NMO-ON (Table I) (2), including 1 case of AQP4 IgG (+) NMO-ON; this patient had a course of disease of 13 years, a right vision at onset of ≤0.1 and a left vision at onset of >0.1, and presented with a recurrent attack of ON in both eyes. After hormone and immunosuppressive therapy, the vision was recovered to be >0.1 in both eyes, and the VFSS score was recovered from 5 to 3 points; the intraorbital segment of the optic nerve was involved, but the intracranial segment, canal segment and optic chiasma were not involved; there were demyelinating lesions in the intracranial semi-oval center, but the spinal cord was not involved. The other case as aforementioned was an AQP4 IgG (-) NMO-ON patient with a course of disease of 16 years and a history of 15 attacks, who presented with a recurrent attack of ON in both eyes, acute myelitis involving >3 segments, postrema syndrome and acute diencephalic syndrome, which used to be diagnosed as ̔multiple sclerosis̓. After interferon treatment, the patient was diagnosed with NMO-ON and treated with hormone and immunosuppressive therapy. The recovery of vision on both eyes was poor (≤0.1); The VFSS score prior to and after treatment was 6 points. Imaging indicated involvement of the intraorbital segment, canal segment, intracranial segment and optic chiasma of bilateral optic nerves, demyelinating lesions in the intracranial medulla oblongata, thalamus, midbrain, corpus callosum, basal ganglia, frontal white matter, lateral ventricle, and medullary C2 and C5-T1.
Discussion
In the present study, 27.91% of RON patients were MOG IgG (+) [including 1 case that was also AQP4 IgG (+)] with a male/female ratio of 1:1.75. In 2015, Matsuda et al (7) detected the MOG antibody in 70 patients with ON, and the results indicated that 18 cases were MOG IgG (+), including 7 males and 11 females (1:1.57), and the MOG IgG (+) rate was 25.7%. The above results were similar to those of the present study.
In the present study, the age at onset, course of disease, onset frequency and other immune indexes of MON IgG (+) RON patients were not significantly different compared with those of AQP4 IgG (+) RON and MON/AQP4 IgG (-) RON patients. However, another study indicated that compared with AQP4 IgG (+) patients, MOG IgG (+) patients were younger at onset, and the prevalence was not higher in females as in the present study (8) . Other studies have reported that the age at onset was not significantly different between MOG IgG (+) and AQP4 IgG (+) patients (9) . In 2015, Nakajima et al (10) detected the MOG antibody in patients with idiopathic ON and determined that MOG IgG (+) patients with idiopathic ON present with eye pain. In this study, 63.6% patients in the MOG IgG (+) group had eye pain, but there was no significant difference compared with the AQP4 IgG (+) and MON/AQP4 IgG (-) groups. In 2014, Sato et al (11) detected that 16 out of 215 NMO-ON patients had a MOG IgG (+) status. It was revealed that those MOG IgG (+) patients had a monophase course compared with AQP4 IgG (+) patients (11) . Furthermore, in this study, the onset frequency was not significantly different between the MOG IgG (+) group and the AQP4 IgG (+) group, which may be due to the fact that all patients in the experiment had a relapsing course, and there was a lack of research on the monophase course.
Through imaging analysis, intraorbital segment involvement of RON was identified in each group of the present study. Compared with those in the MOG IgG (+) group and MOG/AQP4 IgG (-) group, more canal segment and intracranial segment involvement was observed in the AQP4 IgG (+) group. Compared with the MOG/AQP4 IgG (-) group, the optic chiasma was more frequently involved in the AQP4 IgG (+) group. Thus, the involved part of the optic nerve in MOG IgG (+) RON was more forward, but that in the AQP4 IgG (+) RON was more backward, which was similar to the results of Ramanathan et al (12) .
Two protocols were adopted in the present study for the assessment of the worst vision at onset and visual function after recovery. First, the visual changes were directly observed, and the worst vision after onset and better vision after recovery were evaluated with 0.1 as the threshold. Second, the VFSS score was given for the degree of visual impairment prior to and after treatment, and the changes in score were observed.
Regardless of the evaluation protocol, the vision at onset of MOG IgG (+) RON patients was not as poor as that of AQP4 IgG (+) RON patients, and the visual recovery was better in MOG IgG (+) RON patients after hormone with/without immunosuppressive therapy. A number of studies have reported similar results (13) (14) (15) .
In the present study, two cases met the diagnostic criteria for NMO-ON, including 1 case of AQP4 antibody-negative NMO-ON with RON, acute myelitis, postrema syndrome and diencephalic syndrome, which also suggested that MOG may be a potential biomarker for AQP4 IgG (-) NMO-ON. Therefore, for clinical patients with suspected NMO-ON with AQP4 IgG (-) status, the detection of serum MOG antibody may be performed, so as to facilitate early diagnosis and treatment, and thereby improve their prognosis.
Compared with the AQP IgG (+) group, the higher prevalence in females in the MOG IgG (+) RON group was less pronounced, the vision at onset was better, the recovery of visual function after treatment was better, and the involved part of the optic nerve was more forward. MOG IgG may be present in the serum of NMO-ON patients, which may be utilized as a potential biomarker for NMO-ON with AQP4 IgG (-) status.
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